Skip to main content
AEON Biopharma, Inc. logo

AEON Biopharma, Inc. — Investor Relations & Filings

Ticker · AEON ISIN · US00775E1029 US Manufacturing
Open in API
Filings indexed 317 across all filing types
Latest filing 2021-02-26 Audit Report / Informat…
Country US United States of America
Listing US AEON

About AEON Biopharma, Inc.

https://www.aeonbiopharma.com/

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused exclusively on developing therapeutic applications for botulinum toxins. The company is advancing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for the treatment of debilitating nervous system-related and neuromuscular disorders. Its lead clinical programs are investigating ABP-450 for the prevention of chronic and episodic migraines and the treatment of cervical dystonia. By concentrating solely on therapeutic indications, AEON aims to unlock the full potential of neurotoxins to provide lasting relief for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K/A
Audit Report / Information Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. It specifically states it is amending Exhibit 99.1 to include the Report of Independent Registered Public Accounting Firm. The document is short (3743 characters) and primarily serves to amend and provide an audit report as an exhibit to a prior filing. It does not contain a full annual report or comprehensive financial statements itself, but rather an audit report as an exhibit. According to the definitions, standalone audit reports and related information are classified under Audit Report / Information (AR). Therefore, this document is best classified as an Audit Report / Information filing.
2021-02-26 English
PRIVETERRA ACQUISITION CORP.
Major Shareholding Notification
2021-02-22 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about the issuance of a convertible promissory note, the consummation of an IPO, private placement of warrants, and an audited balance sheet as an exhibit. The document is not a full annual or quarterly report but rather a regulatory filing disclosing material events and financial obligations. It does not contain comprehensive financial statements or detailed management discussion typical of annual or interim reports. The presence of exhibits and the nature of the disclosures align with the purpose of an 8-K as a Regulatory Filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-02-18 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about the company's initial public offering (IPO), entry into material definitive agreements related to the IPO, unregistered sales of equity securities, appointment of new directors, amendments to the certificate of incorporation, and other events related to the IPO. It also includes exhibits such as underwriting agreements, warrant agreements, and press releases announcing the IPO pricing and closing. The document does not contain financial statements or detailed financial performance data but rather announces significant corporate events and transactions. Therefore, this filing is best classified as a Capital/Financing Update (CAP) because it primarily reports on the IPO and related financing activities.
2021-02-12 English
424B4
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(4) related to a public offering of units by Priveterra Acquisition Corp., a blank check company (SPAC). It details the offering size, unit composition, underwriting arrangements, use of proceeds, and other offering-related information. The document is a registration and offering prospectus, not a financial report, earnings release, or management discussion. It is a detailed disclosure document for investors about the capital raising and securities offering. This fits the category of Capital/Financing Update (CAP) because it provides updates on the company's fundraising and capital structure changes through the public offering. The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the correct classification is CAP with high confidence.
2021-02-11 English
S-1MEF
Regulatory Filings Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, specifically a Rule 462(b) filing to register additional securities related to a prior S-1 registration statement. It includes legal opinions, consents, and signatures but does not contain financial statements or performance data. The document is a regulatory filing related to securities registration under the Securities Act of 1933, not a financial report or earnings release. Therefore, it fits the category of Regulatory Filings (RNS).
2021-02-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.